Replies to post #17500 on Innovus Pharmaceuticals Inc. (fka INNV)

[WiseInvestor8]

Hi Batermere,
You wrote: "We haven’t had any real “news” since the Q2 ER almost two months ago. They did PR that they would be attending the Wainwright Annual Global Investment Conference seven weeks ago ..."
Does this released article below at Yahoo Finance from Zacks Small Cap Research count as a PR? Afterall, INNV paid Zacks to write this report.
"INNV: Targeting high-demand consumer health needs with innovative products" by Beth Senko, CFA, Zacks Small Cap Research, 10/4/2018.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services.
The article is essentially a summary of important facts that the management wanted to tell investors about their company INNV. This may just be a hint from Dr. Damaj about the good things to come.
INNV sells 32 products and expects to add four to five more by year-end.
Innovus has a strong pipeline and a very active direct marketing effort.
Experienced staff and internal metrics will enable the Company to improve its story to investors, manage growth, and ultimately increase investor confidence in the company and its business strategy,.
Financials: Rapid top-line growth, strong gross margins – operating leverage ahead
Sensitivities and risks: Execution is key
Valuation: Significant upside on modest assumptions

[LW89]

You are incorrect. They were at Wainwright. Bassam did not make the trip, but Ryan did.